Novo Nordisk slides as Ozempic pill fails to slow Alzheimer’s disease progression in large trials (NVO:NYSE)

hapabapa/iStock Editorial via Getty Images

Novo Nordisk (NVO) fell nearly 10% in U.S. premarket trading on Monday after the Danish drugmaker said a pill version of Ozempic (semaglutide) did not slow the progression of Alzheimer’s disease in two large studies that had aimed to explore a